期刊文献+

左炔诺孕酮宫内缓释系统对增生过长子宫内膜的雌孕激素受体的影响 被引量:31

Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia
下载PDF
导出
摘要 目的用形态计量学方法分析左炔诺孕酮宫内缓释系统(LNG-IUS)放置前后增生过长子宫内膜局部雌孕激素受体变化,以探讨LNG-IUS治疗子宫内膜增生过长患者的有效性。方法观察25例无排卵型功血患者增生过长子宫内膜LNG-IUS放置前后子宫内膜组织学变化,用免疫组化法测定雌激素受体(ER)、孕激素受体(PR)含量变化。结果 LNG-IUS放置后6个月子宫内膜增殖受到明显抑制,表现为子宫内膜腺体数目明显减少,腺体发育不良,间质细胞有明显的蜕膜样变。治疗前大部分腺体上皮和间质细胞ER、PR免疫着色显示为强染。治疗后子宫内膜雌孕激素受体表达下降,腺上皮细胞和间质细胞中ER、PR阳性细胞数均明显减少。结论 LNG-IUS可抑制子宫内膜增殖,降低雌孕激素受体表达,对于治疗简单型和复杂型子宫内膜增生过长的患者是有效的。 Objective To investigate the changes in local endometrial contents of estrogen receptors (ER) and progesterone receptors (PR) after insertion of levonorgestrel-releasing intrauterine system (LNG-IUS) and evaluate the efficacy of LNG-IUS in treating endometrial hyperplasia. Methods The endometrial histological changes were observed in 25 anovulatory women with dysfunctional uterine bleeding after insertion of LNG-IUS, and the contents of ERs and PRs in the endometerium were measured by immunohistochemistry. Results The endometrial proliferation activity was obviously inhibited 6 months after LNG-IUS insertion with decreased endometrial glands, glandular dysplasia and dedualization of interstitial cells. The positive cell rate for ERs and PRs in the glandular epithelial and interstitial cells were significantly reduced after LNG-IUS insertion. Conclusions LNG-IUS can reduce ER and PR expressions in the endometrium and inhibit endometrial proliferation, and therefore can be effective in treating simple and complex endometrial hyperplasia.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2012年第9期1350-1354,共5页 Journal of Southern Medical University
基金 广东省科技计划项目(2010B031600201)
关键词 子宫内膜增生 左炔诺孕酮宫内缓释系统 雌激素受体 孕激素受体 endometrial hyperplasia levonorgestrel-releasing intrauterine system estrogen receptors progesterones receptors
  • 相关文献

参考文献15

  • 1曹泽毅.中华妇产科学[M].2版.北京:人民卫生出版社,2004:2163-2169.
  • 2Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up[J]. Maturitas, 2007, 57(2): 210-3.
  • 3Higham JM, O' Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart[J]. Br J Obstet Gynecol, 1990, 97 (8): 734-9.
  • 4许良中.乳腺病删学[M].上海:上海医科大学出版社,1999:332-43.
  • 5Xiao BL, Zhou LY, Zhang XL, et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device[J]. Contraception, 1990, 41 (4): 353-62.
  • 6Beatty MN, Blumenthal PD. The levonorgestrel-releasing in- trauterine system: Safety, efficacy, and patient acceptability [J]. Ther Clin Risk Manag, 2009, 5(3): 561-74.
  • 7Gomes MK, Rosa-e-Silva JC, Garcia SB, et al. Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium[J]. Hum Reprod, 2008, 24(11 ): 2736-45.
  • 8Bergeron C, Ferenczy A, Shyamala G. Distribution of estrogen receptors in various cell types of normal, hyperplastic, and neoplastic human endometrial tissues [J]. Lab Invest, 1988, 58(3): 338-45.
  • 9Critchley HO, Wang H, Kelly RW, et al. Progestin receptor isofonns and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system [J]. Hum Reprod, 1998, 13(5): 1210-7.
  • 10Zhu P, Liu X, Luo H, et al. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use[J]. Hum Reprod, 1999, 14(4): 970-5.

二级参考文献16

  • 1Lasky JA, Ortiz LA. Antifibrotic therapy for the treatment of pulmonary fibrosis[ J ]. Am J Med Sci, 2001,322(4) : 213-222.
  • 2Barnard JA, Lyins RM, Moses HI. The cell biology of transforming growth factor beta [J]. Biochem Biophys Acta, 1990,1032 ( 1 ) :79- 87.
  • 3Inan S,Vatansever S,Celik-Ozenci C,et al. Immunolocalizations of VEGR, its receptors fit-1, KDR and TGF-beta's in epithelial ovarian tumors[ J ].Histol Histopathol, 2006,21 (10) : 1055-1064.
  • 4Shigeoka Y, Igishi T, Matsumoto S, et al. Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibi- tion[J]. Cancer Res Clin Oncol,2004, 130(3 ) : 146-152.
  • 5Berger DH,Ko CY,Spain DA. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell- cell matrix interactions[ J ]. Surgery, 2003,133 (5) : 568-579.
  • 6Parekh TV, Gama P, Wen X, et al. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition [J]. Cancer Res,2002,62 (10) : 2778-2790.
  • 7Carcamo J, Zentella A, Massague J. Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex[J]. Mol Cell Biol, 1995,15(3):1573- 1581.
  • 8Maliekal TT, Antony ML, Nair A, et al. Loss of expression, and mutations of Smad 2 and smad 4 in human cervical cancer[ J ]. Oncogene, 2003,22(3) :4889-4897.
  • 9Jin X, Gossett DR, Wang S, et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells[J]. Br J Cancer,2004,91 (10) : 1808-1812.
  • 10Brian B, Moses HL.TGF-]3 and cancer [J].Cytokine& Growth Factor Reviews, 2006,17 ( 1-2 ) : 29-40.

共引文献623

同被引文献186

引证文献31

二级引证文献362

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部